Acute feeding studies
Acute feeding studies provide an excellent screening platform to quickly understand the hypophagic potential of a novel drug. These assays are typically performed in lean mice or rats but can also be performed in...
FIND OUT MORE
Adriamycin-induced model of focal segmental glomerulosclerosis (FSGS) and fibrosis
Focal segmental glomerulosclerosis (FSGS) is one of the most common causes of primary glomerular diseases in adults. FSGS is induced in rodents by administration of adriamycin (anthracycline also called doxorubicin). Structural and functional injury...
FIND OUT MORE
Anti-GBM Model of nephrotoxic nephritis and inflammation
Glomerulonephritis (GN) is a group of diseases involving damage to the glomeruli caused by inflammation. We have developed the antibody induced anti-GBM (glomerular basement membrane) rodent model of glomerulonephritis that mimics human GN by rapid...
FIND OUT MORE
Aqueous solubility – turbidimetric / kinetic – thermodynamic
Low solubility can be a major obstacle during drug discovery and development, as low solubility can impact the generation of quality in vitro DMPK or biology data, can cause issues in the generation of an appropriate...
FIND OUT MORE
Assessment of Energy Expenditure
The mechanisms underlying the reduction in body weight produced by novel anti-obesity drugs should always be investigated by measuring the effects of the compound on both sides of the energy equation balance. Energy Expenditure...
FIND OUT MORE
Assessment of gastric emptying rate to explore mechanisms of satiety and reduced food intake
The inhibition of gastric emptying has been linked to satiety and reduced food intake. We offer direct (phenol red recovery) and indirect (serum APAP) models of gastric emptying, depending on your project requirements. This...
FIND OUT MORE
Behavioural aspects of feeding to explore specificity of effects on food intake
When a drug reduces gross food intake following acute administration, several different studies can be performed to confirm that it is acting specifically on the mechanisms controlling food intake, rather than producing non-specific behavioural...
FIND OUT MORE
Binge Eating Disorder
Sygnature has successfully developed and validated a new rat model of binge-eating disorder. Rats are given free access to normal rat diet and irregular access to chocolate for limited periods (2 h). After 3-4...
FIND OUT MORE
Blood Plasma Partitioning
Certain drugs are highly bound to red blood cells (RBC) whilst others are highly bound to plasma proteins. As pharmacokinetics are mostly measured from plasma samples, binding to RBC can lead to dramatically miscalculated...
FIND OUT MORE
Body composition analysis to determine specificity of weight loss
Body composition analysis can be used to investigate whether weight loss is accounted for by a clinically beneficial selective loss of fat, or by producing non-specific decreases in water (dehydration) and/or protein content (muscle...
FIND OUT MORE
Caco-2 Permeability
The human colon epithelial cancer cell line, Caco-2, is used as a model of human intestinal absorption of drugs. This model is suitable to test compound suitability for oral dosing, predict intestinal permeability and...
FIND OUT MORE
Chemical Stability
The measurement of the stability of a drug in conditions that mimic the gastrointestinal tract, physiological conditions and/or in vitro biological conditions helps in identifying and understanding the lability of molecules due to non-enzymatic processes. High...
FIND OUT MORE
CYP Induction (mRNA) / HepaRG
Cytochrome P450 (CYP) induction by a drug can accelerate the metabolism of a co-administered victim drug significantly, causing serious drug-drug interactions. To date induction of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 have been...
FIND OUT MORE
Cytotoxicity testing
Cell viability or cytotoxicity assessments are based on cellular functions that are particularly sensitive to toxic drugs, and as such provide convenient in vitro high-throughput screens (HTS) for comparing relative toxicities of a drug....
FIND OUT MORE
Dietary-induced obese (DIO) mice and rats
Dietary-induced obese (DIO) mice and rats are well-established animal models of obesity that offer proven predictive validity of clinically effective weight loss drugs. Our DIO mouse model is ready to use, therefore enabling a...
FIND OUT MORE
Drug Discrimination
Most CNS drugs produce a pharmacologically specific interoceptive cue in rats that they can use to differentiate between the training drug and vehicle. Drug discrimination testing using abused drugs as the training cues is...
FIND OUT MORE
Early assessment of abuse potential.
Sygnature offers a range of models that can be used to explore the pharmacological profiles of novel drugs compared to known drugs of abuse, allowing the early assessment of abuse potential. Locomotor activity All...
FIND OUT MORE
Genetic models of insulin resistance and type 2 diabetes
We have extensive experience of working with animal models that are genetically predisposed to developing insulin resistance and progressive type 2 diabetes. Depending on the therapeutic indication, for example, insulin resistance or overt diabetes,...
FIND OUT MORE
Glucocorticoid-induced model of insulin resistance
We have developed a rapid model of insulin resistance induced by sub-chronic administration of the glucocorticoid, cortisone, resulting in significantly increased plasma glucose and insulin levels within 7 days in rats. This model can be used...
FIND OUT MORE
Glucose and insulin tolerance testing
Glucose tolerance testing via a variety of routes, i.e. OGTT, ipGTT, ivGTT) in mice and rats is a measure of how efficiently an exogenously delivered glucose load is cleared from the blood. Moreover, the...
FIND OUT MORE
H-FFC CCl4 model of severe fibrosis and NASH
Non-alcoholic fatty liver disease (NAFLD) is a complex spectrum of liver diseases ranging from simple hepatic steatosis through to non-alcoholic steatohepatitis (NASH) which can ultimately lead to end-stage liver disease. Patients with NASH who...
FIND OUT MORE
H-FFC mouse model of NASH and fibrosis
Non-alcoholic steatohepatitis (NASH) and liver fibrosis are associated with an increased risk of developing hepatocellular carcinoma and ultimately end-stage liver disease. In the clinic NASH is often accompanied with metabolic syndrome, specifically obesity, type...
FIND OUT MORE
Hepatocyte Metabolic Stability
The liver is the major site of drug metabolism in the body, with well over 50% of marketed drugs eliminated via hepatic mediated metabolism. Hence, measurement of the rate of clearance and the identity...
FIND OUT MORE
In vivo PK / Pharmacokinetic studies
Pharmacokinetics describes the relationship between drug concentration and time in an organism following administration. Explicitly, pharmacokinetics is the study of drug absorption, distribution, metabolism and elimination (ADME). Typically, the first in vivo experiment during an...
FIND OUT MORE
Intracerebral microdialysis
Sygnature is a leading provider of intracerebral microdialysis services in rats and mice. Our dedicated team of experts have been conducting microdialysis studies for more than 20 years and can design bespoke studies to...
FIND OUT MORE
LogD (Micro Shake-Flask)
Highly lipophilic compounds (logD7.4 > 3.5) are likely to have: Poor aqueous solubility that can compromise intestinal absorption High first-pass metabolism, leading to high in vivo clearance and contributing to low oral bioavailability High binding...
FIND OUT MORE
MDCK-WT/MDR1 Permeability
Wild-type MDCK (Madin-Darby canine kidney) cells, when transfected with either the Multidrug Resistance gene-1 (MDR1; P-gp) or Breast Cancer Resistance gene (BCRP), are used as a model of brain penetration and to understand the...
FIND OUT MORE
Metabolite Profiling
Although metabolism of drugs, or xenobiotics in general, occurs in a variety of tissues – such as the intestinal wall, lung, kidneys, skin and blood – the liver is regarded as the major site...
FIND OUT MORE
Microsomal Clearance/Stability
The liver is the major site of drug metabolism in the body, with well over 50% of marketed drugs being eliminated via hepatic mediated metabolism. Hence, measurement of the rate of clearance and the...
FIND OUT MORE
P450 / CYP Inhibition
Inhibition of cytochrome P450 (CYP450) enzymes is one of the major reasons for drug-drug interactions (DDI), as they play a significant role in the metabolism of both endogenous and exogenous compounds. Therefore, detailed CYP...
FIND OUT MORE